Search

Cutting-edge practice in glaucoma care: what, how and why?

More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

Clinical and management strategies in glaucoma practice: perspectives from international glaucoma specialists

Management options and outcomes in glaucoma practice were reviewed at the 7th Moorfields International Glaucoma Symposium, held in London on 24 January 2015. This article summarises perspectives from international glaucoma specialists on debated issues in topical therapy, glaucoma surgery, diagnostic...

Rare eye diseases: progress continues with authorised orphan medicines and breakthrough technologies

An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...

Sharing best practice and landmark evidence in glaucoma care

Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...

The science of glaucoma management: highlights of the 2020 Moorfields International Glaucoma Symposium

Held earlier this year, the 12th annual Moorfields International Glaucoma Symposium provided a forum for advanced clinical and scientific exchange in glaucoma management. The authors describe the key presentation themes and debates, highlighting specific topics of interest to glaucoma specialists....

Pharmacopoeia of the Royal Infirmary of Edinburgh

The compact volume depicted in Figure 1 bears the simple title Pharmacopoeia. The book originally belonged to the author’s father, the late John King. A pharmacist by profession, John King maintained a keen interest in matters pertaining to pharmaceutical history....

Optimising the ocular surface by managing meibomian gland dysfunction

Meibomian gland dysfunction (MGD) is ubiquitous. Ocular surface inflammation and irritation are prevalent in most ophthalmology clinics: corneal, cataract, glaucoma, oculoplastic, paediatric, vitreo-retinal, medical retina and refractive surgery. These patients also represent roughly one third of those attending for emergency...

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....